SEPN Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Septerna, Inc.

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

a month ago - By: Septerna, Inc.

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

2 months ago - By: Septerna, Inc.

Septerna to Participate in Upcoming Investor Conferences

2 months ago - By: Septerna, Inc.

Septerna to Participate in Upcoming Investor Conferences

4 months ago - By: Benzinga

The Analyst Verdict: Septerna In The Eyes Of 4 Experts

5 months ago - By: Benzinga

Where Septerna Stands With Analysts

2 months ago - By: Septerna, Inc.

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

3 months ago - By: Septerna, Inc.

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

3 months ago - By: Septerna, Inc.

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

5 months ago - By: Septerna, Inc.

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

5 months ago - By: Zacks Investment Research - Mentions: NVO LLY LXRX

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

5 months ago - By: Investor's Business Daily - Mentions: LLY NVO HIMS CVS ...

Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly

5 months ago - By: Septerna, Inc.

Septerna to Present at Jefferies Global Healthcare Conference

5 months ago - By: Septerna, Inc.

Septerna to Present at Jefferies Global Healthcare Conference

5 months ago - By: Zacks Investment Research

Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect?

5 months ago - By: Septerna, Inc.

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

5 months ago - By: Zacks Investment Research - Mentions: NVO LLY AMGN

Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk

6 months ago - By: Investor's Business Daily - Mentions: AAPL NVO

Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing

6 months ago - By: Stocktwits - Mentions: NVO NVDA

Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled

6 months ago - By: Bloomberg

SEPTERNA INC (SEPN) Stock News

SEPN Latest News, Press Relases and Analysis

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

Septerna to Participate in Upcoming Investor Conferences

Septerna to Participate in Upcoming Investor Conferences

The Analyst Verdict: Septerna In The Eyes Of 4 Experts

Where Septerna Stands With Analysts

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly

Septerna to Present at Jefferies Global Healthcare Conference

Septerna to Present at Jefferies Global Healthcare Conference

Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect?

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk

Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing

Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled

Novo Nordisk, Septerna in $2.2 Billion Obesity Pill Partner Deal